Agios Pharmaceuticals, Inc.AGIONASDAQ
Loading
Year-over-year research & development expense growth
3Y CAGR
+12.5%/yr
vs -14.4%/yr prior
Acceleration
+26.9pp
Accelerating
Percentile
P36
Within normal range
vs 3Y Ago
1.4x
Solid growth
Streak
2 yr
Consecutive growthStable
| Period | Value |
|---|---|
| 2025 | 12.70% |
| 2024 | 4.29% |
| 2023 | 3.21% |
| 2022 | 8.93% |
| 2021 | 21.78% |
| 2020 | -48.64% |
| 2019 | 20.38% |
| 2018 | 16.62% |
| 2017 | 32.94% |
| 2016 | 55.23% |